The stock of Scilex Holding Company (SCLX) has gone up by 47.71% for the week, with a 96.75% rise in the past month and a 17.52% rise in the past quarter. The volatility ratio for the week is 14.17%, and the volatility levels for the past 30 days are 12.51% for SCLX. The simple moving average for the past 20 days is 41.35% for SCLX’s stock, with a 5.76% simple moving average for the past 200 days.
Is It Worth Investing in Scilex Holding Company (NASDAQ: SCLX) Right Now?
SCLX has 36-month beta value of 1.10. Analysts have mixed views on the stock, with 0 analysts rating it as a “buy,” 0 as “overweight,” 0 as “hold,” and 0 as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for SCLX is 118.28M, and currently, short sellers hold a 5.98% ratio of that float. The average trading volume of SCLX on June 17, 2024 was 946.18K shares.
SCLX) stock’s latest price update
Scilex Holding Company (NASDAQ: SCLX)’s stock price has soared by 8.05 in relation to previous closing price of 1.49. Nevertheless, the company has seen a gain of 47.71% in its stock price over the last five trading days. globenewswire.com reported 2024-06-14 that PALO ALTO, Calif., June 14, 2024 (GLOBE NEWSWIRE) — Scilex Holding Company (Nasdaq: SCLX, “Scilex” or the “Company”), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain, today announced the publication of results of the pivotal registration trial of SP-102 (SEMDEXA™) in PAIN, the official journal of the International Association for the Study of Pain, which features original research on the nature, mechanisms and treatment of pain.
Analysts’ Opinion of SCLX
Many brokerage firms have already submitted their reports for SCLX stocks, with Rodman & Renshaw repeating the rating for SCLX by listing it as a “Buy.” The predicted price for SCLX in the upcoming period, according to Rodman & Renshaw is $13 based on the research report published on June 13, 2024 of the current year 2024.
B. Riley Securities, on the other hand, stated in their research note that they expect to see SCLX reach a price target of $4. The rating they have provided for SCLX stocks is “Buy” according to the report published on October 16th, 2023.
B. Riley Securities gave a rating of “Buy” to SCLX, setting the target price at $4 in the report published on October 13th of the previous year.
SCLX Trading at 50.59% from the 50-Day Moving Average
After a stumble in the market that brought SCLX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -80.60% of loss for the given period.
Volatility was left at 12.51%, however, over the last 30 days, the volatility rate increased by 14.17%, as shares surge +85.06% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +5.23% upper at present.
During the last 5 trading sessions, SCLX rose by +47.71%, which changed the moving average for the period of 200-days by -46.60% in comparison to the 20-day moving average, which settled at $1.1760. In addition, Scilex Holding Company saw -21.08% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at SCLX starting from SHAH JAISIM, who purchase 56,939 shares at the price of $0.92 back on May 17 ’24. After this action, SHAH JAISIM now owns 155,882 shares of Scilex Holding Company, valued at $52,099 using the latest closing price.
Chun Jay, the Director of Scilex Holding Company, purchase 57,500 shares at $0.90 during a trade that took place back on May 17 ’24, which means that Chun Jay is holding 102,500 shares at $51,641 based on the most recent closing price.
Stock Fundamentals for SCLX
Current profitability levels for the company are sitting at:
- -2.26 for the present operating margin
- 0.62 for the gross margin
The net margin for Scilex Holding Company stands at -2.29. The total capital return value is set at 0.66. Equity return is now at value -163.31, with -121.78 for asset returns.
Based on Scilex Holding Company (SCLX), the company’s capital structure generated -1.38 points at debt to capital in total, while cash flow to debt ratio is standing at -0.03. The debt to equity ratio resting at -0.58. The interest coverage ratio of the stock is -66.45.
Currently, EBITDA for the company is -101.28 million with net debt to EBITDA at -1.07. When we switch over and look at the enterprise to sales, we see a ratio of 8.54. The receivables turnover for the company is 1.58for trailing twelve months and the total asset turnover is 0.52. The liquidity ratio also appears to be rather interesting for investors as it stands at 0.15.
Conclusion
To put it simply, Scilex Holding Company (SCLX) has had a mixed performance in recent times. Analysts have a mixed opinion on the stock, with some rating it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
